Clinical use of brain volumetry

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 1, 2013, Pages 1-14

  Giorgio, Antonio ^a   De Stefano, Nicola ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Alzheimer's disease; brain atrophy; epilepsy; multiple sclerosis; parkinsonisms; volumetric MRI

Indexed keywords

ANTICONVULSIVE AGENT; FINGOLIMOD; GLATIRAMER; HOMOTAURINE; NATALIZUMAB; PEGINTERFERON BETA1A;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ATROPHY; BRAIN SIZE; BRAIN VOLUMETRY; CADASIL; COMPARATIVE STUDY; CONFLICT OF INTEREST; CORTICAL DYSPLASIA; DISEASE COURSE; ENTORHINAL CORTEX; FOCAL EPILEPSY; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPAL SCLEROSIS; HUMAN; MEDICAL EDUCATION; MEDICAL LITERATURE; MIGRAINE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PEER REVIEW; PHYSICIAN; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; TEMPORAL LOBE EPILEPSY; VOLUMETRY;

ALZHEIMER DISEASE; AUTOMATION; BIOLOGICAL MARKERS; BRAIN; BRAIN MAPPING; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROLOGY; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 84872865066     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23671     Document Type: Review

References (137)

1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
2. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM,. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E,. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
5. Bouwman FH, Verwey NA, Klein M, et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010; 30: 1-7.
6. Frisoni GB, Prestia A, Zanetti O, et al. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement 2009; 5: 307-317.
7. Barnes J, Ourselin S, Fox NC,. Clinical application of measurement of hippocampal atrophy in degenerative dementias. Hippocampus 2009; 19: 510-516.
8. Pennanen C, Kivipelto M, Tuomainen S, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004; 25: 303-310.
9. Teipel SJ, Flatz WH, Heinsen H, et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 2005; 128: 2626-2644.
10. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198-208.
11. Neary D, Snowden J, Mann D,. Frontotemporal dementia. Lancet Neurol 2005; 4: 771-780.
12. Pereira JM, Williams GB, Acosta-Cabronero J, et al. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology 2009; 72: 1653-1660.
13. Whitwell JL, Przybelski SA, Weigand SD, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 2009; 132: 2932-2946.
14. Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D,. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. Journal of neurology, neurosurgery, and psychiatry 2001; 70: 323-332.
15. Rohrer JD, Warren JD, Modat M, et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009; 72: 1562-1569.
16. Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL,. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005; 128: 2612-2625.
17. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM,. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6: 67-77.
18. Davatzikos C, Resnick SM, Wu X, Parmpi P, Clark CM,. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. NeuroImage 2008; 41: 1220-1227.
19. Bernasconi A, Bernasconi N, Bernhardt BC, Schrader D,. Advances in MRI for 'cryptogenic' epilepsies. Nat Rev Neurol 2011; 7: 99-108.
20. Wiebe S, Blume WT, Girvin JP, Eliasziw M,. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311-318.
21. Vattipally VR, Bronen RA,. MR imaging of epilepsy: strategies for successful interpretation. Neuroimaging Clin N Am 2004; 14: 349-372.
22. Mechanic-Hamilton D, Korczykowski M, Yushkevich PA, et al. Hippocampal volumetry and functional MRI of memory in temporal lobe epilepsy. Epilepsy Behav 2009; 16: 128-138.
23. Mathern GW, Babb TL, Vickrey BG, Melendez M, Pretorius JK,. The clinical-pathogenic mechanisms of hippocampal neuron loss and surgical outcomes in temporal lobe epilepsy. Brain 1995; 118 (Pt 1): 105-118.
24. Bast T, Ramantani G, Seitz A, Rating D,. Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults. Acta Neurol Scand 2006; 113: 72-81.
25. Salmond CH, Ashburner J, Vargha-Khadem F, Connelly A, Gadian DG, Friston KJ,. Distributional assumptions in voxel-based morphometry. NeuroImage 2002; 17: 1027-1030.
26. Colliot O, Bernasconi N, Khalili N, Antel SB, Naessens V, Bernasconi A,. Individual voxel-based analysis of gray matter in focal cortical dysplasia. NeuroImage 2006; 29: 162-171.
27. Besson P, Andermann F, Dubeau F, Bernasconi A,. Small focal cortical dysplasia lesions are located at the bottom of a deep sulcus. Brain 2008; 131: 3246-3255.
28. Colliot O, Antel SB, Naessens VB, Bernasconi N, Bernasconi A,. In vivo profiling of focal cortical dysplasia on high-resolution MRI with computational models. Epilepsia 2006; 47: 134-142.
29. Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246: 214-221.
30. Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64: 2050-2055.
31. Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011; 26: 527-533.
32. Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63: 81-86.
33. Ginestroni A, Battaglini M, Della Nave R, et al. Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study. J Neurol 2009; 256: 925-932.
34. Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 2003; 53: 181-188.
35. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006; 5: 828-834.
36. Bouwman FH, Schoonenboom SN, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007; 28: 1070-1074.
37. Desikan RS, Fischl B, Cabral HJ, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71: 819-825.
38. Likeman M, Anderson VM, Stevens JM, et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch Neurol 2005; 62: 1410-1415.
39. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73: 294-301.
40. Misra C, Fan Y, Davatzikos C,. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. NeuroImage 2009; 44: 1415-1422.
41. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71: 743-749.
42. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
43. Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010; 31: 758-764.
44. Barnes J, Scahill RI, Frost C, Schott JM, Rossor MN, Fox NC,. Increased hippocampal atrophy rates in AD over 6 months using serial MR imaging. Neurobiol Aging 2008; 29: 1199-1203.
45. Bermel RA, Bakshi R,. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158-170.
46. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO,. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 1994; 51: 874-887.
47. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-1691.
48. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141-147.
49. Sbardella E, Tomassini V, Stromillo M, et al. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2011; 17: 1432-1440.
50. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L,. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704.
51. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000; 54: 807-812.
52. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G,. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-1718.
53. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F,. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59: 1572-1576.
54. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-1876.
55. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive gray matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-1107.
56. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH,. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 327-337.
57. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162.
58. Chard DT, Griffin CM, Rashid W, et al. Progressive gray matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387-391.
59. Battaglini M, Giorgio A, Stromillo ML, et al. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J Neurol Sci 2009; 282: 55-60.
60. Prinster A, Quarantelli M, Orefice G, et al. Gray matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. NeuroImage 2006; 29: 859-867.
61. Sepulcre J, Sastre-Garriga J, Cercignani M, Ingle GT, Miller DH, Thompson AJ,. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006; 63: 1175-1180.
62. Charil A, Dagher A, Lerch JP, Zijdenbos AP, Worsley KJ, Evans AC,. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. NeuroImage 2007; 34: 509-517.
63. Jasperse B, Vrenken H, Sanz-Arigita E, et al. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. NeuroImage 2007; 38: 529-537.
64. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126: 1734-1744.
65. Carone DA, Benedict RH, Dwyer MG, et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. NeuroImage 2006; 29: 505-514.
66. Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM,. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003; 60: 1949-1954.
67. Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-1223.
68. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM,. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650-653.
69. Mesaros S, Rocca MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008; 70: 1107-1112.
70. Aubert-Broche B, Fonov V, Ghassemi R, et al. Regional brain atrophy in children with multiple sclerosis. NeuroImage 2011; 58: 409-415.
71. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280-285.
72. Ge Y, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson DL,. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001; 220: 606-610.
73. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005; 64: 1001-1007.
74. Fisher E, Lee JC, Nakamura K, Rudick RA,. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255-265.
75. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420.
76. Benedict RH, Zivadinov R,. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006; 245: 67-72.
77. Rao SM, Bernardin L, Leo GJ, Ellington L, Ryan SB, Burg LS,. Cerebral disconnection in multiple sclerosis. Relationship to atrophy of the corpus callosum. Arch Neurol 1989; 46: 918-920.
78. Pozzilli C, Bastianello S, Padovani A, et al. Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. Cortex 1991; 27: 441-445.
79. Pelletier J, Suchet L, Witjas T, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-111.
80. Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain 2008; 131: 1134-1141.
81. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008; 71: 632-638.
82. Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004; 63: 89-93.
83. Morgen K, Sammer G, Courtney SM, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. NeuroImage 2006; 30: 891-898.
84. Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26: 341-346.
85. Bakshi R, Benedict RH, Bermel RA, Jacobs L,. Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 2001; 11: 129-136.
86. Keller SS, Roberts N,. Voxel-based morphometry of temporal lobe epilepsy: an introduction and review of the literature. Epilepsia 2008; 49: 741-757.
87. Labate A, Cerasa A, Gambardella A, Aguglia U, Quattrone A,. Hippocampal and thalamic atrophy in mild temporal lobe epilepsy: a VBM study. Neurology 2008; 71: 1094-1101.
88. Keller SS, Mackay CE, Barrick TR, Wieshmann UC, Howard MA, Roberts N,. Voxel-based morphometric comparison of hippocampal and extrahippocampal abnormalities in patients with left and right hippocampal atrophy. NeuroImage 2002; 16: 23-31.
89. Kuzniecky R, Jackson GD,. Magnetic resonance in epilepsy. Neuroimaging techniques. New York: Academic Press; 2005.
90. Ho SS, Kuzniecky RI, Gilliam F, Faught E, Morawetz R,. Temporal lobe developmental malformations and epilepsy: dual pathology and bilateral hippocampal abnormalities. Neurology 1998; 50: 748-754.
91. Matharu MS, Good CD, May A, Bahra A, Goadsby PJ,. No change in the structure of the brain in migraine: a voxel-based morphometric study. Eur J Neurol 2003; 10: 53-57.
92. Yilmaz-Kusbeci O, Gocmen-Mas N, Yucel A, Karabekir HS, Ertekin T, Yazici AC,. Evaluation of cerebellar and cerebral volume in migraine with aura: a stereological study. Cerebellum 2010; 9: 345-351.
93. Rocca MA, Ceccarelli A, Falini A, et al. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke 2006; 37: 1765-1770.
94. Schmidt-Wilcke T, Ganssbauer S, Neuner T, Bogdahn U, May A,. Subtle gray matter changes between migraine patients and healthy controls. Cephalalgia 2008; 28: 1-4.
95. Kim JH, Suh SI, Seol HY, et al. Regional gray matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia 2008; 28: 598-604.
96. DaSilva AF, Granziera C, Snyder J, Hadjikhani N,. Thickening in the somatosensory cortex of patients with migraine. Neurology 2007; 69: 1990-1995.
97. May A, Matharu M,. New insights into migraine: application of functional and structural imaging. Curr Opin Neurol 2007; 20: 306-309.
98. Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology 2005; 65: 1483-1486.
99. Woolf CJ, Salter MW,. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-1769.
100. May A,. Chronic pain may change the structure of the brain. Pain 2008; 137: 7-15.
101. Mackenzie IR, Feldman HH,. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 2005; 64: 730-739.
102. Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 400-403.
103. Agosta F, Chio A, Cosottini M, et al. The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2010; 31: 1769-1777.
104. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR,. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010; 75: 1645-1652.
105. O'Sullivan M, Jouvent E, Saemann PG, et al. Measurement of brain atrophy in subcortical vascular disease: a comparison of different approaches and the impact of ischaemic lesions. NeuroImage 2008; 43: 312-320.
106. Jouvent E, Mangin JF, Porcher R, et al. Cortical changes in cerebral small vessel diseases: a 3D MRI study of cortical morphology in CADASIL. Brain 2008; 131: 2201-2208.
107. Peters N, Holtmannspotter M, Opherk C, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology 2006; 66: 1517-1522.
108. Stromillo ML, Dotti MT, Battaglini M, et al. Structural and metabolic brain abnormalities in preclinical cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. J Neurol Neurosurg Psychiatry 2009; 80: 41-47.
109. Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H,. Cortical neuronal apoptosis in CADASIL. Stroke 2006; 37: 2690-2695.
110. O'Sullivan M, Ngo E, Viswanathan A, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging 2009; 30: 890-897.
111. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253-260.
112. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009; 13: 550-557.
113. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-2011.
114. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E,. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-682.
115. Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2008; 29: 1285-1295.
116. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600.
117. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM,. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 20954-20959.
118. McEvoy LK, Edland SD, Holland D, et al. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24: 269-277.
119. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64: 236-240.
120. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.
121. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD,. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003; 9: 21-27.
122. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ,. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
123. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-144.
124. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123 (Pt 11): 2256-2263.
125. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54: 813-817.
126. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M,. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004; 62: 1432-1434.
127. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247.
128. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68: 1390-1401.
129. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
130. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
131. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-529.
132. Giorgio A, Battaglini M, Smith SM, De Stefano N,. Brain atrophy assessment in multiple sclerosis: importance and limitations. Neuroimaging Clin N Am 2008; 18: 675-686.
133. Battaglini M, Jenkinson M, De Stefano N,. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2011 [Epub ahead of print].
134. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA,. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010; 32: 223-228.
135. Nakamura K, Fox R, Fisher E,. CLADA: cortical longitudinal atrophy detection algorithm. NeuroImage 2011; 54: 278-289.
136. Akhondi-Asl A, Jafari-Khouzani K, Elisevich K, Soltanian-Zadeh H. Hippocampal volumetry for lateralization of temporal lobe epilepsy: automated versus manual methods. NeuroImage 2010; 54 (Suppl 1): S218-226.
137. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T,. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol 2006; 6: 17.